Status:
UNKNOWN
Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.
Lead Sponsor:
Hospital of Prato
Conditions:
Pharmacological Action
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
PHASE3
Brief Summary
There is no specific antiviral treatment recommended for COVID-19, and no vaccine is currently available. Baricitinib, an anti-Janus kinase inhibitor (anti-JAK) acting against JAK1 and JAK2. The drug ...
Detailed Description
Study design. Interventional, open-label, 2-week, prospective trial of a cohort of patients with mild to moderate COVID-19 infection. Objectives. Primary. To assess the efficacy of baricitinib combin...
Eligibility Criteria
Inclusion
- All consecutive patients with mild to moderate COVID-19 infection
- Age \>18 years,
- Clinical diagnosis of COVID19 infection
- Patients should present fever, cough and myalgia and weakness and radiological findings of pneumonia.
- All patients should be willing and able to provide written informed consent prior to performing study procedures.
Exclusion
- Age less than 18
- History of thrombophlebitis.
- Patient with latent tuberculosis infection (Quantiferon test).
- Pregnancy and lactation.
Key Trial Info
Start Date :
May 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04320277
Start Date
May 16 2020
End Date
July 30 2020
Last Update
April 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fabrizio Cantini
Prato, Tuscany, Italy, 59100